VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administere...
Q1 2026
May 15, 2026
FY 2025
Feb 27, 2026
Q4 2025
Q3 2025
Nov 6, 2025
Q2 2025
Aug 14, 2025
